Harmony Biosciences Holdings (HRMY) is drawing attention after reporting second quarter 2026 net income of US$75.43 million, along with record results for WAKIX and updates across several late stage neurology programs.

The recent second quarter results and late stage pipeline updates come after a solid run for Harmony Biosciences Holdings, with a 30 day share price return of 12.88% and a 90 day share price return of 27.79%. Over a longer window, the total shareholder return of 17.55% across three years points to momentum that has been building rather than fading.

If the recent earnings news has you reassessing opportunities in healthcare, this can be a good moment to scan for other rare disease and neurology players within our 42 healthcare AI stocks.

Harmony Biosciences Holdings now combines a recent share price climb with record WAKIX earnings and a busy late stage pipeline. Does that mix still leave enough potential upside to justify the risks at today’s valuation?

Most Popular Narrative: 19.4% Undervalued

The most followed valuation narrative currently pegs Harmony Biosciences Holdings at a fair value of $47.30, compared with the recent close around $38.12. This implies meaningful upside in that framework.

The large and growing patient populations affected by sleep disorders and rare neurodevelopmental conditions, driven by demographic aging and increased recognition/diagnosis, are expanding Harmony's total addressable market, supporting sustained long-term revenue growth for both existing and pipeline products.

This narrative leans on a detailed earnings and revenue roadmap, paired with a specific profit margin profile and a future earnings multiple that sits below the broader pharmaceuticals sector. It raises the question of which assumptions really carry the $47.30 fair value and how sensitive the story is to changes in growth or margins.

The fair value estimate is built using a discount rate of 6.98%, applied to forecast cash flows that include higher revenue, expanding profitability and a modest future P/E multiple compared with wider US pharmaceuticals coverage. It also reflects analyst expectations around earnings growth over the next few years, alongside assumptions for share count and the durability of cash flows from WAKIX and the emerging neurology portfolio.

Result: Fair Value of $47.30 (UNDERVALUED)

However, Harmony Biosciences Holdings still carries real pressure points, with heavy reliance on WAKIX and legal or generic entry risk that could compress the current valuation narrative.

Next Steps

With sentiment around Harmony Biosciences Holdings clearly mixed, this is a good time to act quickly and evaluate the story against your own expectations. Take a closer look at the 4 key rewards.

Looking for more investment ideas beyond Harmony Biosciences Holdings?

If Harmony Biosciences Holdings has sharpened your focus, now is the time to broaden your watchlist with a few targeted stock ideas that fit your style.

• Target potential bargains by scanning companies that combine quality fundamentals with appealing valuations through the 52 high quality undervalued stocks.
• Prioritize resilience and sleep better at night by reviewing companies that feature in the 80 resilient stocks with low risk scores.
• Spot underfollowed opportunities early by checking the screener containing 20 high quality undiscovered gems before others catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.